# Purine derivatives.

## Abstract
Novel purine derivatives, particularly novel guanines and hypoxanthines, are described as agents for treating autoimmune diseases. The compounds have the following formula I CHEM or a pharmaceutically acceptable acid addition or base salt thereof wherein R1 is OH or SH R2 is i hydrogen or ii NHR in which R is hydrogen or COR6 in which R6 is alkyl of one to four carbon atoms, aryl or arylalkyl R3 is hydrogen, hydroxyl, mercapto, bromide or NHR in which R is hydrogen or COR6 n is zero or one, m is zero or one or two or three, with the proviso that m or n is at least one R4 nd R5 are each, independently, hydrogen, alkyl of from one to four carbon atoms, aryl, arylalkyl, cycloalkyl of from three to six carbon atoms or hydroxyalkyl of from one to four carbon atoms and Ar is heteroaryl or heteroaryl substituted by i alkyl of from one to four carbon atoms, ii alkoxy of from one to four carbon atoms, or iii C C C C attached to adjacent carbon atoms of the heteroaryl to form a benzo radical, or iv halogen excluding the compound wherein R1 is OH, R2 is amino, R3 is hydrogen, n is zero, m is one, and Ar is 2 furanyl.

## Claims
CLAIMS for BE,CH,DE,FR,GB,IT,LI,LU,NL,SE 1. A compound of the following formula I EMI63.1 or a pharmaceutically acceptable acid addition or base salt thereof wherein R1 is OH or SH R2 is i hydrogen or ii NHR in which R is hydrogen or COR6 in which R6 is alkyl of one to four carbon atoms, aryl or arylalkyl R3 is hydrogen, hydroxyl, mercapto, bromine or NHR in which R is hydrogen or COR6 in which R6 is alkyl of one to four carbon atoms, aryl or arylalkyl n is zero or one, m is zero or one or two or three, with the proviso that m or n is at least one R4 and R5 are each, independently, hydrogen, alkyl of from one to four carbon atoms, aryl, arylalkyl, cycloalkyl of from three to six carbon atoms or hydroxyalkyl of from one to four carbon atoms and Ar is heteroaryl or heteroaryl substituted by i alkyl of from one to four carbon atoms, ii alkoxy of from one to four carbon atoms, or iii C C C Cattached to adjacent carbons atoms of the heteroaryl so as to form a benzo radical, or iv halogen excluding the compound wherein R1 is OH, R2 is amino, R3 is hydrogen, n is zero, m is one, and Ar is 2 furanyl. 2. A compound as claimed in Claim 1, or a pharmaceutically acceptable acid addition or base salt thereof, wherein R1 is OH or SH R2 is hydrogen or NH2 R3 is hydrogen, hydroxyl, mercapto, bromine or NH2 n is zero or one and m is zero or one, with the proviso that at least one of n and m must be one R4 and R5 are each, independently, hydrogen, alkyl of from one to four carbon atoms or hydroxyalkyl of from one to four carbon atoms and Ar is 2 or 3 furanyl, 2 or 3 thienyl, or 2 , 3 , or 4 pyridinyl, or 2 or 3 furanyl, 2or 3 thienyl, 2 , 3 , or 4 pyridinyl or 2 , 4 , or 5thiazolyl sustituted by i an alkyl of from one to four carbon atoms, ii an alkoxy of from one to four carbon atoms, iii a C C C C radical attached to adjacent carbons of the heteroaryl so as to form a benzo radical, or iv halogen. 3. A compound as claimed in Claim 1 or 2, wherein R1 is OH R2 is NH2 R3 is hydrogen, hydroxyl, mercapto, bromine or NH2 at least one of n and m is one, and Ar is 2 or 3 furanyl, 2 or 3 thienyl or 2 , 3 , or 4 pyridinyl, or 2 or 3 furanyl, 2 or 3 thienyl, 2 , 3 , or 4 pyridinyl, or 2 , 4 , or 5 thiazolyl, substituted by methyl, ethyl, or C C C C attached to adjacent carbons of the heteroaryl so as to form a benzo radical. 4. A compound as claimed in Claim 1, 2 or 3, wherein Ar is 2 or 3 furanyl substituted by methyl or ethyl. 5. A compound as claimed in Claim 1, 2 or 3, wherein Ar is 2 or 3 thienyl substituted by methyl or ethyl. 6. A compound as claimed in Claim 1, 2 or 3, wherein Ar is 2 , 3 , or 4 pyridinyl substituted by methyl or ethyl. 7. A compound as claimed in Claim 1, 2 or 3, wherein Ar is 2 , 4 , or 5 thiazolyl substituted by methyl or ethyl. 8. A compound as claimed in Claim 6, and being 9iC 3 pyridinyl methylguanins 9 E 2 thienylmethyl guanine 9 2 pyridinyl methyl guanine 9 5 ethyl 2 thienyl methyl guanine 8 bromo 9 2 thienylmethyl guanine 8 bromo 9 5 ethyl 2 thienyl methyl guan 8 bromo 9 2 furanylmethyl guanine 8 bromo 9 3 pyridinyl methyl guanine 8 amino 9 5 ethyl 2 thienyl methyl guan 8 amino 9 2 thienyl methyl guanine or the monochloride, hemihydrate thereof 8 amino 9 3 pyridinyl methyl guanine 9 3 methyl 2 thienyl methyl guanine 9 2 methyl 3 thienyl methyl guanine 9 benzo b thien 3 yl methyl guanine 9 3 thienyl methyl guanine 9 2,5 dimethyl 3 thienyl methyl guanine 9 3 furanylmethyl guanine 8 bromo 9 2 furanylmethyl guanine 8 bromo 9 2 methyl 3 thienyl methyl guanine 8 bromo 9 benzo b thien 3 yl methyl guanine 8 bromo 9 2 thienyl methyl guanine 8 amino 9 2 furanylmethyl guanineOr the monohydrochloride hydrate therf 8 amino 9 3 thienyl methyl guanine or the monochloride monohydrate thereof 8 amino 9 3 methyl 2 thienyl methyl guanine or the 0.25 H20 compound thereof 8 amino 9 benzo b thien 3 yl methyl guanine or the hemihydrate thereof methyl 2 amino 6,9 dihydro 6 oxo 9 2 thienylmethyl 1H purin 8 yl carbamate ethyl 2 amino 6,9 dihydro 6 oxo 9 2 thienylmethyl 1H purin 8 yl carbamate 8 amino 9 3 furanyl methyl guanine or the hydrochloride thereof 8 amino 9 2 2 thienyl ethyl guanine or the hydrochloride monohydrate thereof 8 amino 9 2 methyl 3 thienyl methyl guanine or the hydrochloride sall thereof 8 amino 9 5 methyl 2 thienyl methyl guanine 8 amino 9 2 pyridinyl methyl guanine or the 1.5 HC1 0.25 H20 salt thereof 8 amino 9 benzo b thien 2 yl methyl guanine or the 0.25 H20 hydrate thereof 8 amino 9 2 thiazolyl methyl guanine 8 amino 9 4 thiazolyl methyl guanine 8 amino 9 2 3 thienyl ethyl guanine. or 0.9 HC1 monohydrate thereof 8 amino 9 5 methyl 3 thienyl methyl guanine or the hydrochloride hemihydrate thereof 8 amino 9 5 methyl 2 furanyl methyl guanine or the hydrochloride 1.15 H20 compound thereof 8 amino 9 4 methyl 3 thienyl methyl guanine 8 amino 9 4 methyl 2 thienyl methyl guanine 2, 8 diamino i, 9 dih dro 9 2 t nienylmethyl 6EI purine 6 thione j 2, 8 diaminol, 9 dihydro 9 3 thienylmeEhyl 6H. purine 6 thlone j 2, 8 diamino 1, 9 dihydro 9 2 2 thienyl ethyl 6H purine 6 thione 2 amino 7,9 dihydro 9 2 thienylmethyl purine 6, 8 dione 2 amino 1,7,8,9 tetrahydro 9 2 thienylmethyl 8 thioxo 6H purin 6 one or N,N 6,9 dihylro 6 oxo 9 2 thienylmethyl 1H purin2,8 diyl bisacetamide. 9. A pharmaceutical composition comprising an effective amount of a compound as claimed in any preceding claim together with a pharmaceutically acceptable carrier or diluent. 10. For use in a method of treating autoimmune diseases in mammals suffering therefrom, a compound as claimed in any one of Claims 1 to 8 or a pharmaceutical composition according to Claim 9. 11. A process for the preparation of a compound of formula I according to Claim 1 wherein R2 is NH2, and of the formula I EMI70.1 which comprises reacting a compound of the formulaEMI70.2 with formic acid and formaraide at elevated temperatures to obtain a compound of Formula I wherein R2 is NH2 and R3 is hydrogen, and if desired, converting the resulting compound into a compound of Formula I wherein R3 is Br, and further into a compound of Formula I wherein R3 is NHR wherein R is hydrogen or COR6 and then into a pharmaceutically acceptable acid addition or base salt thereof. 12. A process for the preparation of a compound according to Claim 1 wherein R2 is 2, and of the formulaEMI71.1 which comprises treating a compound of the formulaEMI71.2 with N bromosuccinimide in an organic solvent, and, if desired, converting the resulting compound into a pharma ceutically acceptable acid addition or base salt thereof. 13. A process for the preparation of a compound according to Claim 1, wherein R3 is ER, which comprises reacting a compound of the formulaEMI72.1 with hydrazine at elevated temperatures and, optionally, with Raney nickel in an alcohol solvent, and, if desired, converting the resulting compound there R is hydrogen to a compound were R is COR5 with an alkanoyl halide, aroyl halide, or arylalkanoyl halide in the presence of an organic base, and, if desired, where R1 is O or OH, converting said compound to a compound where R1 isS or SH and, if further desired, converting the resulting compound to a pharmaceutically acceptable acid addition or base salt thereof. 14. A compound of theEMI73.1 wherein R6 is alkyl of one to four carbon atoms, aryl, or arylalkyl n is zero or one m is zero, one, two, or three, with the proviso that m or n is at least one R4 and Rs are each independently hydrogen, alkyl of one to four carbon atoms, aryl, arylalkyl, or cyclo alkyl of three to six carbon atoms, hydroxy alkyl of one to four carbon atoms, and Ar is heteroaryl or heteroaryl substituted by alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, C C C C attached to adjacent carbons so as to form a benzo radical, or halogen. 15. A compound of the formulaEMI73.2 wherein R6 is alkyl of one to four carbon atoms, aryl, arylakyl n is zero or onet 10 iS zero, one, two, or three, with the proviso that m or n is at least one R4 and R5 are each independently hydrogen, alkyl of one to four carbon atoms, aryl, arylalkyl or cycloalkyl of three to six carbon atoms, hydroxyalkyl of one to four carbon atoms, and Ar is heteroaryl or heteroaryl substituted by alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, C C C C attached to adjacent carbons so as to form a benzo radical, or halogen. 16. A compound of the formulaEMI74.1 wherein n is zero or one m is zero, one, t, or three, with the proviso that m or n is at least one R4 and R5 are each independently hydrogen, alkyl of one to four carbon atoms, hydroxyalkyl of one to four carbon atoms, and Ar is heteroaryl or heteroaryl substituted by alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms C C C attached to adjacent carbons so as to form a benzo radical, or halogen. 17. A process for the preparation of a compound according to Claim 1 which comprises heating a compound of theEMI74.2 wherein R4, R5, 4, n, m, and Ar are as defined in Claim 1 to obtain the compound of Formula I wherein R1 is 08 and R3 is NHCOR6 wherein in presence of a base such as t2C03 in an alcoholic solvent such as methanol R6 is alkyl of from one to four carbon atoms, aryl or arylalkyl, and if desired, converting said compound of Formula I wherein R1 is 08 to a compound where R1 is S or SH. 18. A process for the preparation of a compound according to Claim 14,which comprises contacting a compound of the formulaEMI75.1 wherein R4, R5, R6, n, m, and Ar areas defined in Claim 16 with a coupling agent such as N,N dicyclohexylcarbondiimide, in the presence of a solvent to obtain the compound of Formula III. 19. A process according to Claim 18 wherein the compound of Formula II is prepared by 1 reacting 2 amino 6 chloro 4 pyrimidinol withEMI75.2 wherein R4, R5, Ar, n, and X are as defined above 2 treating the product of 1 with an aqueous solution of sodium nitritet 3 treating the product of 2 with sodium dithionite in formamide and formic acid to obtain a compound of formula EMI76.1 wherein R4, R5, n, m, and Ar are defined above 4 treating the compound of Formula IV in anhydrous methanolic anhydrous 8C1 to obtain a compound of formulaEMI76.2 wherein R4, R5, n, m, and Ar are defined above 5 treating the compound IVa.HCl with hydrazine in aqueous NE40H to give the free base IVa or alternatively, treating the compound from step 2 above or the corresponding nitro comound such as 2 amino 6 substituted amino 5 nitro 4 pyrmidi nol prepared from 2 amino 6 chloro 5 nitro 4pyrimidinol and the amine A by catalvtic reduction and 6 treating the product of step 5 with R6OOCNCS wherein R is methyl or ethyl to obtain the compound of Formula II. CLAIMS for AT 1. A process for the preparation of a compound of the formula I EMI77.1 or a pharmaceutically acceptable acid addition or base salt thereof wherein R1 is OH or SH R2 is i hydrogen or ii NHR in which R is hydrogen or COR6 in which R6 is alkyl of one to four carbon atoms, aryl or arylalkyl R3 is hydrogen, hydroxyl, mercapto, bromine or NHR in which R is hydrogen or COR6 in which R6 is alkyl of one to four carbon atoms, aryl or arylalkyl n is zero or one, m is zero or one or two or three, with the proviso that m or n is at least one R4 and R5 are each, independently, hydrogen, alkyl of from one to four carbon atoms, aryl, arylalkyl, cycloalkyl of from three to six carbon atoms or hydroxyalkyl of from one to four carbon atoms and Ar is heteroaryl or heteroaryl substituted by i alkyl of from one to four carbon atoms, ii alkoxy of from one to four carbon atoms, or iii C C C Cattached to adjacent carbons atoms of the heteroaryl so as to form a benzo radical, or iv halogen excluding the compound wherein R1 is OH, R2 is amino, R3 is hydrogen, n is zero, m is one, and Ar is 2 furanyl which process comprises reacting a compound of the formula IV EMI77.2 with formic acid and formamide at elevated temperatures, to obtain a compound of the formulaEMI78.1 and, if desired, converting the thus formed compound into a compound of Formula 1 wherein R1 is SH and or R3 is hydroxyl, Br, mercapto, or NHR whrein R is as defined above or a pharmaceutically acceptable acid addition or base salt thereof. 2. A process for the preparation of a compound of the formulaEMI78.2 wherein R2, R4, R5, n, m and Ar are as defined in Claim 1, which process comprises treating a compound of the formulaEMI78.3 with N bromosuccinimide in an organic solvent, and, if desired, converting the resulting compound into a pharmaceutically acceptable acid addition or base salt thereof. 3. A process for the preparation of a compound of the Formula I as defined in Claim 1 wherein R3 isNHR and R is as defined in Claim 1 which process comprises reacting a compound of the formulaEMI79.1 wherein R2, R4, R5, n, m, and Ar are as defined inClaim 1, with hydrazine at elevated temperatures and, optionally, with Raney nickel in an alcohol solvent, and, if desired, converting the resulting compound where R is hydrogen to a compound where R is COR6 with an alkanoyl halide, aroyl halide, or arylalkanoyl halide in the presence of an organic base, and, if desired, where R1 is O or OH, converting said compound to a compound where Rg is S or SH and, if further desired, converting the resulting compound to a pharmaceutically acceptable acid addition or base salt thereof. 4. A process for the preparation of a compound of Formula I as defined in Claim 1 which comprises heating a compound of the formula EMI80.1 wherein R4, R5, R6, n, m, and Ar are as defined inClaim 1 to obtain the compound of Formula I wherein R1 is OH and R3 is NHCOR6 wherein, in presence of a base such as K2C03 in an alcoholic solvent such as methanol,R6 is alkyl of from one to four carbon atoms, aryl or arylalkyl, and if desired, converting said compound ofFormula I wherein R1 is OH to a compound where R1 is S or SH. 5. A process for preparing a compound of the formula IV EMI80.2 wherein R2, R4, R5, n, m and Ar are as defined inClaim 1, which process comprises 1 reacting 2 amino 6chloro 4 pyrimidinol withEMI80.3 2 treating the product of 1 with an aqueous solution of sodium nitrite 3 treating the product of 2 with sodium dithionite in formamide and formic acid to obtain the desired compound of formula IV 6. A process for the preparation of a compound having the following formEMI81.1 wherein R2, R4, R5, R6, n, m and Ar are as defined inClaim 1 which process comprises contacting a compound of the formula EMI81.2 with a coupling agent such as N,N dicyclohexylcarbondiimide, in the presence of a solvent to obtain the compound of Formula III. 7. A process for the preparation of a compound of the formulaEMI81.3 which process comprises 1 reacting 2 amino 6 chloro4 pyrimidinol with EMI82.1 wherein R4, R5, Ar, n, and m are as defined above 2 treating the product of 1 with an aqueous solution of sodium nitrite 3 treating the product of 2 with sodium dithionite in formamide and formic acid to obtain a compound of formulaEMI82.2 wherein R4, R5, n, m, and Ar are defined above 4 treating the compound of Formula IV in anhydrous methanolic anhydrous HC1 to obtain a compound of formulaEMI82.3 wherein R4, R5, n, m, and Ar are defined above 5 treating the compound IVa.HC1 with hydrazine in aqueous NH40H to give the free base IVa or alternatively, treating the compound from step 2 above or the corresponding nitro comound such as 2 amino 6 substituted amino 5 nitro 4 pyrimidinol prepared from 2 amino 6 chloro 5 nitro 4 pyrimidinol and the amine A by catalytic reduction and 6 treating the product of step 5 with R600CNCS wherein R is methyl or ethyl to obtain the compound of Formula II. 8. A process according to any one of Claims 1 to 7, wherein R1 is OH or SH R2 is hydrogen or NH2 R3 is hydrogen, hydroxyl, mercapto, bromine or NH2 n is zero or one and m is zero or one, with the proviso that at least one of n and m must be one R4 and R5 are each, independently, hydrogen, alkyl of from one to four carbon atoms or hydroxyalkyl of from one to four carbon atoms and Ar is 2 or 3 furanyl, 2 or 3 thienyl, or 2 , 3 , or 4 pyridinyl, or 2 or 3 furanyl, 2 or 3 thienyl, 2 , 3 , or 4 pyridinyl or 2 , 4 , or 5 thiazolyl substituted by i an alkyl of from one to four carbon atoms, ii an alkoxy of from one to four carbon atoms, iii a C C C C radical attached to adjacent carbons of the heteroaryl so as to form a benzo radical, or iv halogen. 9. A process according to Claim 1, 2, 3, 4 or 8, wherein R1 is OH R2 is NH2 R3 is hydrogen, hydroxyl, mercapto, bromine or NH2 at least one of n and m is one, and Ar is 2 or 3 furanyl, 2 or 3 thienyl or 2 , 3 , or 4 pyridinyl, or 2 or 3 furanyl, 2 or 3 thienyl, 2 , 3 , or 4 pyridinyl, or 2 , 4 , or 5 thiazolyl, substituted by methyl, ethyl, or C C C C attached to adjacent carbons of the heteroaryl so as to form a benzo radical. 10. A process according to Claim 1, 2, 3, 4, 8 or 9, wherein Ar is 2 or 3 furanyl substitued by methyl or ethyl. 11. A process according to Claim 1, 2, 3, 4, 8 or 9, wherein Ar is 2 , 3 thienyl substituted by methyl or ethyl. 12. A process according to Claim 1, 2,3,4, 8 or 9, wherein Ar is 2 , 3 , or 4 pyridinyl substituted by methyl or ethyl. 13. A process according to Claim 1, 2, 3, 4, 8 or 9, wherein Ar is 2 , 4 , or 5 thiazolyl substituted by methyl or ethyl. 14. A process according to Claim 1, 2, 3 or 4 in which one of the following compounds is prepared 9 3 pyridinyl methyl guanine 9 2 thienylmethyl guanine 9 2 pyridinyl methyl guanine 9 5 ethyl 2 thienyl methyl guanine 8 bromo 9 2 thienylmethyl guanine 8 bromo 9 5 ethyl 2 thienyl methyl guanine 8 bromo 9 2 furanylmethyl guanine 8 bromo 9 3 pyridinyl methyl guanine 8 amino 9 5 ethyl 2 thienyl methyl guanine 8 amino 9 2 thienyl methyl guanine or the monochloride, hemihydrate thereof 8 amino 9 3 pyridinyl methyl guanine 9 3 methyl 2 thienyl methyl guanine 9 2 methyl 3 thienyl methyl guanine 9 benzo b thien 3 yl methyl guanine 9 3 thienyl methyl guanine 9 2,5 dimethyl 3 thienyl methyl guanine 9 3 furanylmethyl guanine 8 bromo 9 2 furanymelthyl guanine 8 bromo 9 2 methyl 3 thienyl methyl guanine 8 bromo 9 benzo b thien 3 yl methyl guanine 8 bromo 9 2 thienyl methyl guanine 8 amino 9 2 furanylmethyl guanine or the monohydrochloride hydrate of the compound monohydrochloride hydrate of the compound 8 amino 9 3 thienyl methyl guanine or the monochloride mnchydrate thereof 8 amino 9 3 methyl 2 thienyl methyl guanine or the 0.25 H20 corn pound thereof 8 amino 9 benzo b thien 3 yl methyl guanine or the hemihydrate thereof methyl 2 amino 6,9 dihydro 6 oxo 9 2 thienyl methyl 1H purin 8 yl carbamate ethyl 2 amino 6,9 dihydro 6 oxo 9 2 thienylmethyl 1H purin 8 yl carbamate 8 amino 9 3 furanyl methyl guanine or the hydrochloride thereof 8 amino 9 2 2 thienyl ethyl guanine or the hydrochloride monohydrate thereof 8 amino 9 2 methyl 3 thienyl methyl guanine or the hydrochloride salt thereof 8 amino 9 5 methyl 2 thienyl methyl guanine 8 amino 9 2 pyridinyl methyl guanine or the 1.5 HCl 0.25 H2O salt thereof 8 amino 9 benzo b thien 2 yl methyl canine or the 0.25 H20 hydrate thereof 8 amino 9 2 thiazolyl methyl guanine 8 amino 9 4 thiazolyl methyl guanine 8 amino 9 2 3 thienyl ethyl guanine or 0.9 HC1 monohydrate thereof 8 amino 9 5 methyl 3 thienyl methyl guanine or the hydrochloride hemihydrate thereof 8 amino 9 5 methyl 2 furanyl methyl guanine or the hydrochloride i.15 H2 0 compound thereof 8 amino 9 4 methyl 3 thienyl methyl guanine 8 amino 9 4 methyl 2 thienyl methyl guanine 2,8 diamino 1,9 dihydro 9 2 thienylmethyl 6Hpurine 6 thione 2,8 diamino 1,9 dihydro 9 3 thienylmethyl 6Hpurine 6 thione 2,8 diamino 1,9 dihydro 9 2 2 thienyl ethyl 6H purine 6 thione 2 amino 7,9 dihydro 9 2 thienylmethyl 1Hpurine 6,8 dione 2 amino 1,7,8,9 tetrahydro 9 2 thienylmethyl 8 thioxo 6H purin 6 one orN,N 6,9 dihydro 6 oxo 9 2 thienylmethyl 1Hpurin 2,8 diyl bisacetamide. 15. A process for preparing a pharmaceutical composition, which process comprises combining a compound prepared in accordance with any preceding claim together with a pharmaceutically acceptable carrier or diluent. 16. For use in a method of treating autoimmune diseases in mammals suffering therefrom, a compound prepared by a process as claimed in any one of Claims 1 to 14 or a pharmaceutical composition prepared by a process as claimed in Claim 15.

## Description
PURINE DERIVATIVES 8 Aminoguanine, a compound known since the turn of the century, has been reported to have PNP activity byR. Parks, et. al., in Biochem. Pharm., 31 2 , 163 1982 . 9 2 Furfuryl guanine is a known compound described in J. Am. Chem, Soc., 81 3046 1959 having no disclosed utility. The present invention is related to novel purine derivatives not obvious to an ordinarily skilled artisan, particularly, 9 heteroaryl guanines as having PNP inhibiting activity. 8 Amino 9 benzylguanine was discussed at the 16thAnnual Graduate Student Meeting in Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan.However, the present compounds are not obvious from either the synthesis or biological activity of 8 amino9 bensylguanine discussed. With regard to various novel processes of the present invention Ji Wang Chern, et al, describe AConvenient Synthesis of 2 N methoxycarbonylaminooxazolo 5,4 d pyrimidines in J. Het. Chem. 21, 1245 6 1984 . A similar synthesis is described byS. Ram, et al, in A Synthesis of CarbamicAcid Imidazo Heteroaromatic Methyl Ester DerivativesUsing Methoxycarbonyl Isothiocynate, Heterocycles, Vol. 22, No. 8, 1984, pp 1789 90, in which methoxycarbonyl isothiocyanate is used in a one pot reagent for the ring closure of an o diaminopyrimidine derivative to afford a purine derivative possessing the methoxycarbonyylamino functionality at position eight.Further, the mechanism of these two synthesis is discussed by Ji Wang Chern, et al, in The Novel RingOpening of an Oxazolo 5,4 d Pyrimidine and SubsequentRearrangement to Form an Imidazo 4,5 d Pyrimidine,Heterocycles, Vol. 22, No. 11, 1984, pp 2439 2441. None of the disclosures include a disclosure of reaction conditions, or an Ar as a heteroaryl or substituted heteroaryl, substituent defined hereinafter for the compound of Formula I prepared by the novel processes of the present invention. That is, corresponding Ar groups as defined hereinafter for each of the novel intermediates III, II, and I to be heteroaryl or substituted heteroaryl are not included in the above references and furthermore are not obvious variants thereof. SUMMARY OF THE INVENTION The present invention relates to a compound of the formulaEMI3.1 wherein R1 is OH or sa R2 is hydrogen, NHR in whicn R is hydrogen or CDR6 where R6 is alkyl of one to four carbon atoms, aryl or arylaleyl R3 is hydrogen, hydroxyl, mercapto, bromine or NHR where R is nydrogen or CONT wherein i6 is as defined aDove n is zero or one m is zero, one, two, or three, wit the proviso that m or n is at least one Rq and 5 are each independently hydrogen, alkyl of one to four carbon atoms, hydroxyalkyl of one to four carbon atoms, aryl, arylall or cycloalkyl of three to six carbon atoms, and Ar is heteroaryl or heteroaryl substituted by alkyl, alkoxy of one to four carbon atoms, C C C C attached to adjacent carbons so as to form a benzo radical, or halogen or a pharmaceutically acceptable acid or base addition salt thereof, excluding the compound wherein R1 is OH, R2 is amino, R3 is hydrogen, n is zero, rn is one, andAr is 2 furanyl, i.e., 9 2 furanylmethyl guanine. The present invention includes a method of manufacture and a pharmaceutical composition comprising an effective amount of a compound of theFormula I with a pharmaceutically acceptable carrier, as well as a method of treatment of auto immune diseases such as arthritis, systemic lupus erythematosus, inflammatory bowel diseases, multiple sclerosis, juvenile diabetes, as well as transplantation, viral infections and cancer by administering an effective amount of a compound of theFormula I in unit dosage form to a host of the disease.That is, the amount is the amount effective for treating each of the autoimmune diseases. It is understood, an ordinarily skilled physician would begin with a less than effective amount for treatment and increase the dose until the desired effect is obtained exercising care to administer an amount less than the amount toxic to the host of the disease. Both the above pharmaceutical composition and method of treatment include as active ingredient 9 2 furfuryl guanine. The present invention also includes the novel intermediates as follows 1 A compound of Formula III wherein R6 is alkyl of one to tour carbon atoms, aryl, or arylalyl is zero or one m is zero, one, two, or three, with the proviso that m or n is at least one 24 and R5 are each independently hydrogen, alkyl of one to four carbon atoms, aryl, arylalkyl, or cycloalicyl of three to six carbon atoms, hydroxyalxyl of one to four carbon atoms, aryl, arylalkyl, or cycloalkyl of three to six carbon atoms, hydroxyalkyl of one to four carbon atoms, and Ar is heteroaryl or heteroaryl substituted by alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms or halogen 2 a compound of Formula II wherein R6, m, R4, R5, and Ar are as defined above and 3 a compound of Formula IV wherein n, m, R4,R5, and Ar are as defined above. Additionally, the novel processes of the present invention are as follows A A novel process for the preparation of a compound of Formula I, wherein R1 is OR or SH,R2 is NEIR wherein R is as defined above, R3 is hydrogen, hydroxyl, mercapto, bromine, or NHR where R is hydrogen or COR6 wherein R6 is as defined above1 and n, m, R4, Rg, and Ar are also as defined above which comprises heating a compound of the Formula III wherein R6, n, m, R4, R5, and Ar are as defined above to obtain the compound of Formula I wherein R1 is OH and R3 is N8COOR6 wherein R6 is as defined above, and if desired, converting said compound to a compound where R1 is S or SH by methods analogous to those known in the art, and if further desired, where R3 is NHCOOR6 converting the compound to a compound where R3 is hydrogen, or NER where R is hydrogen orCOR6 wherein R6 is as defined above also by known methods. Particularly, the above process is for the preparation of 8 amino 9 2 thienyI nethyllquanine. B A process for the preparation of a compound of the formulaEMI5.1 wherein R1, R2, R, R3, R4, Rg, , n, and Ar are as defined above, with the proviso that R3 is not Br, and R3 is not NBR which comprises reacting a compound of the formulaEMI6.1 with formic acid and formamide at elevated temperatures, to obtain a compound of the formulaEMI6.2 and, if desired, converting by methods analogous to those known in the art the compound into a compound ofFormula I wherein R1 is SH and or R3 is hydroxyl, nercapto, or NER wherein R is as defined above or a pharmaceutically acceptable acid addition or base salt thereof. C A process for the preparation of a compound of the formulaEMI6.3 which comprises treating a compound of the formulaEMI7.1 with bromosuccinimide in an organic solvent, and, if desired, converting by methods known in the art the resulting compound into a pharmaceutically acceptable acid addition or base salt thereof. D A process for the preparation of a compound of the Formula I wherein R3 is NHR wherein R is as defined above which comprises reacting a compound of the formulaEMI7.2 wherein R1, R2, R4, 5, n, m, and Ar is as defined aDove witn hydrazine at elevatea temperatures and, optionally, with Raney nicxel ifl an alcohol solvent, and, if desired, converting the resulting compound where R is hydrogen to a compound where R is CORE with an alkanoyl nalide, aroyl halide, or arylalicansyl halide in tne presence of an organic base, and, if desired, where R1 is O or OH, converting said compound to a compound ere Rl is S or SH by known methods, and, if further desired, converting the resulting compound by methods analogous to those known in the art to a pharmaceutically acceptable acid addition or base salt thereof. E A novel process for the preparation of a compound of Formula III herein R6, n, m, R4, Rg, and Ar are as defined above which comprises contacting a compound of the Formula II wherein R6, n, m, R4,R5, and Ar are as defined above, with a coupling agent in the presence of a solvent to obtain the compound of Formula III. The coupling agent of the process is preferably N,N dicyclohexylcarbodiimide. The preferred solvent is anhydrous dimethylformamide. F A novel process for the preparation of a compound of Formula II wherein R6, n, m, R4, Rg, and Ar is as defined above which comprises refluxing a compound of Formula IV wherein n, m, R4, R5, andAr are as defined above in anhydrous methanol with anhydrous HC1 then basified and treated with lower alkoxy carbonyl isothiocyanate to obtain the compound of Formula II. G A novel process for the preparation of a compound of Formula IV wherein n, m, R4, R5, and Ar are as defined above which comprises step 1 reacting 2 amino 6 chloro 4 pyrimidinol in methoxyethanol with arylalkylamine in the presence of triethylamine step 2 then treating the product of step 1 with aqueous sodium nitrite, step 3 reducing the product of step 2 with sodium dithionite in fonnamide and 90 formic acid to obtain the compound ofFormula IV. Under certain circumstances it is necessary to protect either the N or O of intermediates in the above noted process with suitable protecting groups which are known. Introduction and removal of such suitable oxygen and nitrogen protecting groups are well known in the art of organic chemistry see for example, 1 Protective Groups in Organic Chemistry, J. F. W. ZcOmie, ed., New York, 1973 , pp 43ff, 95ff 2 J. F. W. McCmie, Advances in OrganicChemistry, Vol. 3, 191 281 1963 3 R. A. Boresonas, Advances in Organic Chemistry, Vol. 3, 159 190 1963 and 4 J. F. W. McOmie, Chem. BR Ind., 603 1979 . Examples of suitable oxygen protecting groups are benzyl, t butyldLmethylsilyl, methyl, isopropyl, ethyl, tertiary butyl, ethoxyethyl, and the like.Protection of an N H containing moiety is necessary for some of the processes described herein for the preparation of compounds of this invention. Suitable nitrogen protecting groups are benzyl, triphenylmethyl, trialkyl silyl, trichioroethyl carbamate, trichloroethoxycarbonyl, vinyloxycarbamate, and the like. Under certain circumstances it is necessary to protect two different oxygens with dissimilar protecting groups such that one can be selectively removed while leaving the other in place. The benzyl and t butyldimethylsilyl groups are used in this way either is removable in the presence of the other, benzyl being removed by catalytic hydrogenolysis, and t butyldimethylsilyl being removed by reaction with, for example, tetra n butylammonium fluoride. In the process described herein for the preparation of compounds of this invention the requirements for protective groups are generally well recognized by one skilled in the art of organic chemistry, and accordingly the use of appropriate protecting groups is necessarily implied by the processes of the charts herein, although not expressly illustrated. The products of the reactions described herein are isolated by conventional means such as extraction, distillation, chromatography, and the like. The salts of compounds of Formula I described above are prepared by reacting the appropriate base with a stoichometric equivalent of the acid compounds of Formula I to obtain pharmacologically acceptable salts thereof. The compounds of this invention may also exist in hydrated or solvated forms. The above novel processes beginning with G and proceeding through F , and E , or to and including A two obtain the compound of Formula I wherein R1 isOH and R3 is LSHCOOR6 wherein Rg is as defined above may be conducted in a one pot reaction. Further, the lower alkoxy carbonylisothiocyanate may itself be added in the novel process F above or prepared in situ by suspending potassium thiocyanate in acetonitrile and adding methyl chloroformate to the suspension for a mixture which is heated at reflux in the presence of the basified hydrochloride salt ofFormula I in the above process F . DETAILED DESCRIPTION The compounds of Formula I and intermediates ofFormula II and IV of the present invention exist in tautomeric forms as purines or guanines as illustrated below. Both forms are included as part of the invention and are indiscriminately described in the specification. EMI11.1 Guanine Purine f f EMI11.2 The term alkyl of one to four carbon atoms means a straight or branched hydrocarbon chain up to four carbon atoms such as, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec butyl or tertiarybutyl. Bydroxyalkyl of one to four carbon atoms1 means the same alkyl radical with a terminal hydroxyl group. The term aryl includes an unsubstituted or substituted aromatic ring such as, phenyl or phenyl substituted by halogen, e.g., fluorine, chlorine, bromine, or iodine, alyl of one to four carbon atoms, such as methyl or ethyl, hydroxy, alkoxy of one to four carbon atoms, such as methoxy or ethoxy, or trifluoromethyl. The term arylalkyl means an aromatic ring attached to an alKyl chain of up to four carton atoms, such as unsubstituted or suDstituted phenyletnyl or benzyl where the substituents on the aromatic ring may be the same as defined above. The term heteroaryl1 means five or six membered aromatic ring containing one or more heteroatoms, sucn as nitrogen, oxygen and sulfur. Preferred radicals are the 2 or 3 furanyl 2 or 3 thienyl the 2 , 3 or 4 pyridyl or 2 , 4 , or 5 thiazolyl radicals. Pharmaceutically acceptable acid addition salts are those derived from inorganic acids such as hydrochloric, sulfuric and the like, as well as organic acids such as methanesulfonic, toluenesulfonic,tartaric acid, and the lie. These salts may also be prepared by standard methods known in the art. Pharmaceutically acceptable base salts are those derived from inorganic bases such as sodium hydroxide, potassium hydroxide or ammonium hydroxide or organic bases such as arginine, N methyl glucamine, lysine and the live. These salts may also be prepared by standard methods known in the art. A preferred embodiment of the present invention is a compound of Formula 1 wherein R1 is OH or SH R2 is hydrogen or NH2 R3 is hydrogen, bromine or NH2 n is zero or one m is zero or one, where n or m dust be one R4 and R5 are each independently hydrogen, alkyl of 1 4 carbon atoms or hydroxyalkyl of one to four carbon atoms, and Ar is 2 or 3 furanyl, 2 or 3 thienyl, or 2 , 3 or 4 pyridyl, or 2 or 3 furanyl, 2 , 4 , or 5 thiazolyl, 2 or 3 thienyl, or 2 , 3 , or 4 pyridyl substituted by alkyl of one to four carbon atoms, or a pharmaceutically acceptable acid addition base salt. Another preferred embodiment of the present invention is a compound of Formula 1 wherein R1 is Oti R2 is NH2 R3 is hydrogen, bromine or Nd2 n is O or 1 m is O or 1, where n or m must be 1, andAr is 2 or 3 furanyl, 2 or 3 thienyl, i , 4 , or 5 thiazolyl, or 2 , 3 or 4 pyridyl, or 2 or 3 furanyl, i or 3 thienyl, 2 , 4 , or 5 thiazolyl, or 2 , 3 , or 4 pyridyl substituted by methyl or ethyl, or a pharmaceutically acceptable acid addition or base salt. Particular embodiments of the present invention include 9 1 3 pyridyl methylIguanine 9 2 thenyl guanine 9 2 pyridyl methyl guanine 9 5 ethyl 2 thienyl methyl guanine 8 bromo 9 2 thienylmethyl guanine 8 bromo 9 5 ethyl 2 thenyl guanine 8 bromo 9 2 furfuryl guanine 8 bromo 9 3 pyridyl methyl guanine 8 amino 9 5 ethyl 2 thenyl guanine 8 amino 9 2 thienylmethyl guanine, and 8 amino 9 3 pyridyl methyl guanine. The most preferred compound is 8 amino 9 2 thienylmethyl guanine. The 8 bromo compounds are not only useful pharmacologically but are also useful as intermediates for preparing certain compounds of the present invention. The compounds of Formula I may be prepared according to Methods B, A, and or C as shown in the following Schemes 1, 2, and 3, respectively. Generally, Method A is preferred. I. Scheme 1 Method BEMI15.1 II. Method B Discussion Compounds of Formula B above may also be used as starting materials and may be prepared by reacting 2 amino 6 chloro 4 hydroxy 5 nitropyrimidine, the compound of formula 2 described in J. Chem. Soc., 1962, p. 4186, with the appropriate heteroaryl alkyl amine of formula 3 in the presence of an organic Dase at elevated temperatures. The resulting compound of the formula 4 is then treated with sodium dithionite and formic acid followed by further treatment with formic acid and formamide at elevated temperatures to afford the compound of Formula 8. Alternative, starting materials of Formula 8 may be prepared according to a modified method ofC. W. Noelland, R. K. Robins in J. Hed. Chem., 5, 55d, 1962 starting with a compound of the Formula S whicn is reacted with an appropriate heteroaryl alkyl amine of Formula 3, then with nitrous acid to form the 5 nitrosopyrimidine, 6, which is reduced and ring closed by treatment witn sodium dithionite, formic acid and formamide as described above. The heteroaryl alkyl amines of Formula 3 are either commercially available or may be prepared by known methods. Treatment of a compound of Formula 8 wit S bromosuccinimide in acetic acid, dimethylformamide or ethanol produces a compound of Formula la wr. cn when treated with hydrazine hydrate gives the hydrazine or directly the 8 amino derivative ofFormula Ib. The reaction of the 8 bromo compound with hydrazine may or may not proceed entirely to the 8 amino compound. Thus wnen the 8 hydrazine compound is obtained, it may be further reacted with R2ney nickel to allow tne reduction to go to completion and afford the desired 8 amino compound.Compounds of formula ib may be further converted by Known methods to provide R6 substituents of formula 1d or, where R1 is 0, converting said compound to a compound of formula Ic where Ri is S by reacting the said compound with P2S5 in presence of a base such as pyridine examples given . III. Scheme 2 Method AEMI18.1 IV. Scheme 3 Method CEMI19.1 Generally, the processes of the present invention as shown in scheme 2 above are as follows A 2 amino 6 chloro 4 pyrimidinol, that may be in the monohydrate form, is suspended in methoxyethanol, in the presence of excess amine or an organic base such as triethylamine. The compound of Formula XXX having n, m, R4, Rg, and Ar as defined above is added to the suspension and heated optimally to a temperature at which the suspension refluxes.Refluxing is continued until thin layer chromatography, for example, with 20 methanol in methylene chloride, shows the reaction producing a compound of Formula XX wherein n, m, R4, Rg, and Ar are as defined above is complete. The reaction mixture having the compound ofFormula XX is then diluted with water and treated with sodium nitrite in the presence of acetic acid. A nitroso of the Formula X again having n, m, R4 Rs, and Ar as defined above is obtained from the treatment by the nitrite as evidenced by a color change and precipitate. The temperature of the treatment is at about room temperature. The treatment mixture having therein the nitroso of Formula X is contacted with sodium dithionite in a solvent mixture such as formamide, formic acid, at a temperature of from 60 90 C, preferably from 7C 80 C The temperature is then raised to the boiling pot of the solvent mixture, approximately 130 140 C for up to an hour, preferably at least 20 minutes, or when the color of the nitroso containing mixture described above disappears and an inorganic salt precipitates. The product of this contact is a compound of the Formula IV wherein n, m, R4, R5, andAr are as defined above. Subsequently, the compound of Formula IV is dried and suspended in an anhydrous solvent such as methanol, ethanol, and the like. The suspension is then treated with a dry acid such as HCl, to form the acid salt shown as, Formula IVa, wherein n, m, R4, R5, and Ar are as defined above, or salt corresponding to the acid used for the treatment. The salt IVa is basified with a concentrated mixture of KH40H and 979 hydrazine to obtain a base of the Formula IVb wherein n, m, R4, R5, and Ar are as defined above. The base is unstable, however, is dried, for example in a vacuum over P205. The dried free base IVb is added to a solution of R6OOCNCS wherein R6 is as defined above. The solution of R6OOCNCS may be prepared by suspending potassium thiocyanate in a solvent such as acetonitrile and treating with slightly less than an equivalent of ClCOOR6 wherein R6 is as defined above at reflux for about one hour, cooled, then stirred to insure all of the alkylchioroformate is reacted before the base IVb is added. The reaction of dried free base rVb with the R6OOCNCS is monitored to completion with thin layer chromatography using silica in 20 methanol in methylene chloride to obtain a compound of Formula II wherein R6, n, m, R4, R5, and Ar is as defined above. A mixture of the compound of Formula II and a coupling agent such as N,N dicyclohexylcarbodiimide, in a solvent such as anhydrous dimethylformamide, is stirred at about room temperature until completion of the reaction is shown by thin layer chromatograph to yield a compound of Formula III wherein R6, n, m,R4, R, and Ar are as defined above. The reaction mixture having the compound ofFormula III and anhydrous potassium carbonate are suspended in a solvent such as anhydrous methanol, and refluxed until thin layer chromatography shows the reaction producing a compound of Formula I wherein R1 is O or OH, R3 is NHCOOR6, wherein R6 is as defined above and n, m, R4, R5, and Ar are as defined above. The compound of Formula I wherein R1, is 0 and OH and R3 is NHCOOR6 may then, if desired be used to produce by known methods a compound ofFormula I wherein R3 is NHR wherein R is as defined above other than COOT. Likewise, a compound of Formula I wherein RI is S or SE may be prepared by known methods from the compounds of Formula I wherein R1 is O or OH. The preparation of compounds IV, II, III, and I may be carried out in one pot. However, separation and purification of each of the compounds IV, II, III, or I may be effected by conventional methods, if desired. Generally the processes of the present invention as shown in Scheme 3 Method C above are as follows A mixture of 2 amino 6 chloropurine, potassium carbonate, and the starting material of the formula shown as 2 in Scheme 3 Method C, that is generally commercially available or can be prepared by methods analogous to those known in the art, are stirred under nitrogen for from about 2 to 48 hours. A mixture of 7 and 9 substituted chloropurines shown as Formula 4 and Formula 5 in Scheme 3 Method C are obtained.The desired compound of Formula 4 is separated and treated with an aqueous acid such as BC1 followed by addition of a weak solution of a base such as NaOH.The mixture is heated to assure it is neutralized followed by conventional separation of the desired product of Formula I wherein R3 is hydrogen.Subsequently, reactions to produce compounds ofPormuls 7 and Formula 8 as shown in Scheme 3 Method C are described above for corresponding steps in Schane I Method B. The compounds of the present invention have been shown to exhibit significant enzyme inhibition activity and cytotoxic activity. In the purine nucleoside phosphorylase PNP 4 enzyme assay, total inhibition was achieved at a concentration less than about 300 micromoles on certain compounds of the present invention. PNP 4 activity was measured radiochemically by measuring the formation of E14 C hypoxanthine from L14 C inosine tBiomedicine, 33, 39 1980 using human erythrocyte as the enzyme source.The same compounds also were found by a standard test HTBA 1 Science, 214, 1137, 1981 to be selectively cytotoxic for T cells in the presence of 2 deoxyguanosine at a similar concentration range and nontoxic to B cell in the presence of the same amount of 2 deoxyguanosineRepresentative examples are showr. in the activity table. Activity TableEMI24.1 tb Example1 SEP Arl SEP or SEP of SEP SEP PNP 4 SEP SEP T Cell SEP odGuo tb Number SEP SEP Ar SEP PrepratiOn SEP l SEP IC50 M SEP 10 SEP pM SEP 1C50 SEP uM tb SEP 1 SEP 3 PY SEP l3 Py SEP i SEP B SEP 1 SEP 21.9 SEP 1 SEP 54.1 tb 2 SEP or SEP 9ai2 Th SEP SEP 1 SEP A SEP or SEP B SEP 1 SEP 0.17 SEP 1 SEP 0.83 tb SEP 12 Th 5 Et SEP 1 SEP B SEP 1 SEP 0.93 SEP 1 SEP SEP 4.15 tb SEP 9b SEP 12 Fu SEP 1 SEP B SEP or SEP A SEP 1 SEP 0.25 SEP 1 SEP 2.57 tb SEP 9c SEP 13 Th SEP 1 SEP A, SEP B, SEP or SEP CI SEP 0.085 SEP 1 SEP 0.49 tb SEP 9d SEP l2 Th 3 CH3l SEP B SEP 1 SEP 4.05 SEP i SEP 8.6 tb SEP lEAd SEP l3 TH 2 C3l SEP A SEP A SEP SEP 1.72 SEP 1 SEP 18.2 tb SEP 16Ac SEP 1CH2 2 Th SEP SEP 1 SEP A SEP 1 SEP 625 SEP SEP 17.6 tb SEP 16Ak SEP 13 TH 5 CH3I SEP A SEP 1 SEP SEP 0.63 SEP 1 SEP 2.8 tb SEP 16Ag SEP 1 SEP l SEP A SEP j SEP 8.45 SEP j SEP 12.5 tb SEP 110ski SEP I SEP 1 tb SEP 1 SEP 1 tb SEP I SEP I SEP I tb SEP 9e SEP 1 SEP B SEP I SEP 3 SEP 1140 SEP I tb SEP IsI SEP I SEP I tb SEP I SEP 1 SEP 1 SEP 1 tb SEP I SEP I SEP 1 tb SEP I SEP I SEP I SEP I tb SEP 1SAe SEP 12 Th 5 Me SEP l SEP A SEP I SEP I tb SEP lEAf SEP 12 Py SEP X SEP A SEP SEP 4.6 tb SEP I SEP I SEP I SEP 1 tb SEP 1 SEP 1 tb pyridine, Th thiophene, Fu furan Since T cells play a central role in immune response, use of the compounds of the invention is contemplated for the immunoregulation of autoimmune disease such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, myasthemia gravis, transplantation, juvenile diabetes, cancer, and viral diseases. The present invention thus includes compositions containing a compound of Formula I in treating disease such as autoimmune disease characterized by abnormal iramune response in warmblooded animals.According to this aspect of the invention, the properties of the compounds of the invention are utilized by administering to a warmblooded animal an effective amount of a pharmaceutical composition containing as the active ingredient at least about 0. 1 percent by weight, based on the total weight of the composition of at least one such compound of the invention. Pharmaceutical compositions of the invention car be formulated in any suitable way, preferably with a inert carrier for administration orally, parenterally, ophthalmically, topically, or by suppository. For example, the compounds of the present invention are formulated into dosage forms such as tablets or syrups by blending with an inert pharmaceutical carrier such as lactose or simple syrup by methods well known in the art. For injectable dosage forms, they are formulated with vehicles such as water, propylene glycol, peanut oil, sesame oil, and the like. In these dosage forms, the active ingredient is from about 0.05 grans to 0.5 grams per dosage unit. The present invention is further illustrated by way of the following examples. EXAMPLE 1 9 3 Pyridinyl methyl guanine 3 Pyridylmethylamine 15.8 ml U.1517 mole was added to a suspension of 2 amino 6 chloro 4 hydroxy 5 nitropyrimidine 14.45 g 0.0758 mol in isopropanol 600 ml . The mixture was heated under reflux for two hours and then stirred overnight at room temperature when the product, 2 amino 4 hydroxy 6 3 pyridyl methylamino 5 nitropyrimidine, crystallized out. The product was filtered, washed with water, and air dried. The crude nitropyrimidine 25.32 g from above was suspended in formamide 150 ml and 908 formic acid 50 ml and the suspension was warmed to 70 C in a water bath. Sodium dithionite was carefully added to the rearm suspension and then boiled for 15 20 minutes. The reaction mixture was diluted with hot water 300 ml , treated with charcoal and then boiled for an additional 20 25 minutes, filtered through celite, cooled and concentrated under reduced pressure to give formamido pyrimidine which was collected by filtration, washed with acetone, and dried under vacuum at 560C. The above product was resuspended in formamide 100 ml and formic acid 8 ml and was heated under reflux for 3.5 hours, poured onto 4u0 ml ice water and then filtered. Two crystallization from boiling water gave the analyticai sample of the desired product 4.5 g mp 3u00C. EXAMPLE 2 The procedure described in Example 1 was repeated to prepare the following 9 heteroaryl or substituted heteroaryl methyl guanines, starting from appropriate heteroaryl or substituted heteroaryl methylamines. 9 2 Thienylmethyl guanine, mp 300 C.9 2 Pyridinyl methyl guanine, mp 300 C.9 2 Furanylmethyl guanine, mp 296 2990C, dec. Known Compound J. Am. Chem. boc., 1959, bl 3U46. 9 3 methyl 2 thienyl methyl guanine, mp 290 C dec .9 2 methyl 3 thienyl methyl guanine, mp 270 C dec .9 benzo b thien 3 yl methyl guanine, mp 300 C dec .9 3 thienylmethyl guanine, mp 320 322 C dec . EXAMPLE 2A 2 Amino 9 2 thienyl methyl 6 chloropurine A mixture of 2 amino 6 chloropurine AldrichChemical Co. 7.47 g U.44 mol , potassium carbonate 6.64 g 0.048 mol , and 3 thenylbromide see US Patent number 3,74t,724 7.8 , u.044 mol in DMF 200 ml was stirred under nitrogen at room temperature for 4d hours. The mixture was filtered and the filtrate evaporated to dryness under vacuum, ethyl ether was added and the precipitate was collected by filtration to give a mixture of 7 and 9 suDstituted chloropurines. A sample of Jure 9isomer was prepared by chromatography on silica gel witn 5 methanol methylene chloride as the eluting solvent to separate it from the 7 isomer.Analytical sample was obtained by crystallization from acetonemethanol mixture, yield 2.36 g, mp softens at 185 C dec and tnen melts at 203 204 C dec . EXAMPLE 28 The procedure described ln. Example 2A was repeated to prepare the following 2 amino 9 heteroaryl or substituted heteroaryl methyl 6 chloropurines, startiong from appropriate heteroaryl or substituted heteroaryl methylhalides. 2 Amino 9 2,5 dimethyl 3 thienyl methyl 6chloropurine, mp 190 192 C starting material 2,5 dimethyl 3 thenyl chloride was prepared according to the lit. procedure Buu Hoi and Nguyen Hoan, sec. Trav. Chim, 1949, 68 5 . 2 Amino 9 3 furanylmethyl 6 chloropurine starting material 3 furfurylchloride was prepared according to lit. procedure S. P. Tanis, Tet. Letts., 1982, 23 3115 . EXAMPLE 2C 9 2,5 dimethyl 3 thienyl methyl guanine A mixture of 2 amino 9 2,5 dimethyl 3thienyl methyl 6 chloropurine 3.8 g, 0.0129 mol and 2N HCl was heated on a steambath for 3.0 hours and then heated under reflux for another hour. At the end of this time 1N NaOH solution was added to the solution till basic and the mixture was heated for another five minutes. The mixture was then acidified witn acetic acid, cooled, and filtered to give 3.6 , of the product. An analytical sample was obtained by chromatography over silica gel using 10 methanol chloroform as eluting solvent, mp 300 C dec . XAMPLE 2D The procedure described in example 2C was repeated to prepared 9 3 thenyl guanine, mp 320 3220 dec . EXAMPLE 28 9 3 furanylmethyl guanine The crude 2 amino 9 3 furfuryl 6 chloropurine 4.74 g, U.0l9 mol was suspended in methanol 175 ml and a solution of sod methoxide, prepared from sodium metal 1.75 g 0.076 g atom , and methanol 75 ml , was slowly added to the suspension, followed by 2 mercaptoethanol 6.1 mi a 6.8 g 0.087 mol and water 0.35 ml . The reaction mixture was heated under reflux N2 atm for two hours, when an additional amount of sodium methoxide from 1,14 g sodium 0.05 g atom and 25 ml methanol was added.After an additional 2.5 hours reflux, the reaction mixture was concentrated under vacuum to 75 ml and then diluted with water 200 ml , and acidified wit acetic acid pd 5.5 . The white ppt. was filtered, washed with water, and dried, yield 4.05 g mp 308 310 C. EXAMPLE 3 9 5 Ethyl 2 thienyl methyl guanine 2 Amino 6 chloro 4 pyrimidinol, monohydrate 22.96 g 0.1193 mole was suspended in methoxyethanol 300 ml and 5 ethyl 2 thenylamine 16.58 g 0.ii93 mole prepared from 2 ethyltniopnene according to the Lit. Procedure, JACS, 1948, 70 4018 was added to the suspension. The resulting solution was neath under reflux for one hour and then 16.b ml of triethylamine was added and the refluxiny continued for an additional 18 nours. The reaction mixture was poured into ice water 600 ml , diluted with acetic acid 1t 0 ml and then tredted wit.h a solution of sodium nitrite 16 g in pater 100 ml .The mixture was stirred at room temperature for 1.5 hours and the resulting salmon colored nitroso compound was collected by filtration and washed witti water. The crude nitrosopyrimidine was then reduced with sodium dithionite in formamide 200 ml and 90 formic acid 100 ml at 700C and then boiled for 20 minutes. The reaction mixture was diluted with water 300 ml and the boiling continued for an additional 30 minutes, filtered hot, and then allowed to crystallize in the refrigerator. The crude N formyl derivative 28 g was collected by filtration, washed with water and air dried and tnen cyclized with formic acid 10 ml and formamide 100 ml at reflux temperature for four hours.The hot reaction mixture was poured into 5ou ml of ice water to give the crane guanine whicn was then purified by dissolving in boiling 1.5 ji t1Cl, treating with charcoal and then precipitating with ammonium hydroxide. The crude guanine was then redissolved in hot 1 N aO solution, treated wit charcoal, filtered and the filtrate acidified with acetic acid to give the desired product which was used in tne next step without further purification. EXAMPLE 4 The procedure described in Example 3 was repealed to prepare 9 2 thenyl guanine, mp 300 C starting from 2 amino 6 chloro 4 pyrimidinol and 2 thenylamine. EXAMPLE 5 8 Bromo 9 2 thienylmethyl guanine N Bromosuccinimide 2.82 g 15.7 mmol was added to a cold 0 C suspension of 9 2 thenyl guanine 3.5 g 14.1 mol in DMF 100 ml and the mixture was stirred for 30 minutes at 0 C and then at room temperature for 24 hours. The reaction mixture was then diluted wit 75 ml of water and filtered. Recrystallization of the product from DMF gave the analytical sample, yield 3.1 g mp 294 295 C dec . EXAMPLE 6 The procedure described in example 5 was repeated to prepare the following 8 bromo 9 substituted heteroaryl methyl guanines, starting froin appropriate 9 substituted heteroaryl methyl guanines in each case.8 bromo 9 5 ethyl 2 thienylmethyl guanine 8 bromo 9 2 furanylmethyl guanine, mp 340 C.8 bromo 9 2 methyl 3 thienyl methyl guanine, mp 280 C dec .8 bromo 9 benzo b thien 3 yl methyl guanine, mp 25c 2600C dec . EXAMPLE 7 8 Bromo 9 3 pyridinyl methyl guanine N Bromosuccinimide 1.59 g 8.95 mmol was added to a suspension of 9 3 pyridyl methyl guanine 2.0 g 8.14 mmol in glacial acetic acid 20 ml and the mixture was stirred at room temperature for 3.5 flours. The reaction mixture was concentrated under reduced pressure and then diluted with water and filtered. The crude product was triturated with water, filtered, and washed with water and dried.Yield 1.91 g vp 300 C. EXAMPLE 8 8 Amino 9 5 ethyl 2 thienylmethyl guanine A mixture of 8 bromo 9 5 ethyl 2 thenyl guanine 6.5 g 18.3 mnol and 60 aqueous hydrazine 200 ml was heated to reflux under nitrogen atmosphere for 20 hours. 2 Methoxyetbanol 50 ml was added and the refluxing continued for an additional 48 hours in the open air. The orange brown solution was cooled, diluted with water 150 ml and allowed to crystallize in the refrigerator overnight. The crude product thus obtained was converted to the hydrochloride salt by recrystallizing from boiling isopropanol and 1 N SC1. Yield, 0.49 g mp 215 218 C, dec. EXAMPLE 9 The procedure described in Example a was repeated to prepare the following 8 amino 9 substituted heteroaryl methyl guanines, starting from appropriate 8 bromo 9 substituted heteroaryl methyl guanines 8 Amino 9 3 pyridyl methyl guanine, mp 300 C and additionally, the following compounds a through e were prepared.a. 8 Amino 9 2 thenyl guanine or 8 aminc 9 L 2 thienyl methyl guanine as hydrochloride salt, 0.5 H20, mp 223 226 C dec .b. 8 Amino 9 2 furanylmethyl guanine monohydrochloride, 1.0 H2O, mp 197 199 C dec .c. 8 Amino 9 3 thienyl methyl guanine, monohydrochloride, monohydrate, rnp 275 278 C dec d. 8 Amino 9 3 methyl 2 thienyl methyl guanine, 0.25 H2O, mp 290 C dec .e. 8 Amino 9 benzo b thien 3 yl methyl guanine, 0.5 H2O, mp 3U00C dec . Starting materials, such as 2 , 3 , or 4 pyridylmethylamines, 2 thenylamine also called 2 aminomethyl thiopnene or i thiophene metnylamine, and 2 furfurylamine are commercially available for example, Aldrich Chemical Company . The substituted thenylamines were synthesized from the substituted tniophenes using a general literature procedure. H. D. Hartough and S. L. Meisel, J. Am. Chem. Soc.,I948, 70 4018 . 2 Amino 6 chloro 4 hydroxy 5 nitropyrimidine was synthesized according to a method described in the literature A. Stuart and H. C. S. Wood,J. Chem. Soc., 1963 4186 . 2 Amino 6 chloro 4 pyrimidinol monohydrate was purchased from Aldrich Chemical Company. EXAMPLE 10 2 Amino 4 2 thienyl methyl amino 5 formamido 6 pyrimidinol a compound of Scheme 2 Formula IV wherein n is one, m is zero, R4 and R5 are hydrogen,Ar is 2 thienyl 2 Amino 6 chloro 4 pyrimidinol, monohydrate 85 , 100.0 g, 0.5197 mole was suspended in methoxyethanol 700 ml and 2 thiophenemethylamine 96 , 61.3 g, 0.5197 mole is added to the suspension. The mixture was neated under reflux for two hours and then 73 mi d 0.726, 0.32 mole of triethylamine was added and the refluxing continued for an additional 18 hours. The reaction was followed by TLC 20 methanolCHCl3. The reation mixture was poured into ice water 1000 ml , diluted with acetic acid 400 ml , and then treated with a solution of sodium nitrite 80 g, 1.16 mole in water 300 ml . The mixture was stirred at room temperature for four hours, and the resulting reddish colored nitroso compound X was collected by filtration and washed with water the reaction was followed by observing the color change in the formation of the precipitate . The crude nitrosopyrimidine of Formula X, of Scheme 2, Formula X, wherein n is one, m is zero, R4 and R5 are each hydrogen and Ar is 2 thienyl prepared above was divided into two batches and each in turn was then reduced with sodium dithionite 2908 70 g, 0.36 mole in formamide 300 ml and 90 formic acid 300 ml at 80 C and then boiled for 20 minutes.The temperature was approximately 130 1400C at this point. The reaction was complete when the red color completely disappears and inorganic salt precipitates. The reaction mixture was diluted with water 300 ml and the boiling continued for an additional 30 minutes, filtered hot, and then allowed to crystallize in the refrigerator. The reaction was monitored to completion by C SiO2 20 CH3OH in CHCi3. The crude N formyl derivative, 2 amino 4 2 thienyl methyl amino 5 formamido 6pyrimidinol, 100 g was collected by filtration, washed with water, and dried and used in the next step without further purification in most cases EXAMPLE 10A The procedure described in Example 10 was repeated to prepare 2 Amino LL 3 thienyl methyl amino 5 formamido 6 pyrimidinol starting from 3 thiophene methyl amine and 2 amino 6 chloro 4 pyrimidinol. EXAMPLE 11 2 Amino 4 L i 2 furanylmethyl amino 5 formamiao 6 pyrimidinol A mixture of 2 amino 6 chloro 5 nitro 4 pyri,ai dinol J. CHem. Soc., 1962, p 186 31.5 g 0.15 mol methanol 1200 ml and furfurylamine 29.1 g u.3 mol was stirred and heated under reflux N2 atm for six hours. Tne reaction mixture was cooled, filtered, washed with water, and air dried to give 34.43 g of yellow solid, lap 286 289 C dec , wnich was used in the next reaction. The crude nitropyrimidine 33.9 g 0.135 mol was suspended in formamide 290 ml and 88a formic acid 145 ml , and tnen warmed up to 80 C. odium dithionite 57 g 0.327 mol was slowly added to the warm 80 85 C suspension over a period of 50 minutes, maintained at tne temperature 85 C for another 30 minutes, then diluted with boiling water i200 ml , and heated the mixture arcund 85 C for anotner 20 minutes when tan colored crystals were forme.The product was filtered off, warmed wit water, and dried over P205 under vacuum overnight. Yield, 23.4 g, mp 246 247 C dec . In most cases these compounds were carried through the reaction sequences without characterization. EXAMPLE 11A The procedure described in Example 11 was repeated to prepare the following 2 amino 4 hetero aryl or substituted heteroaryl methyl amino 5 formamido 6 pyrimidinols, Table 1 starting from appropriate heteroaryl or substituted heteroaryl methylamines and 2 amino 6 chloro 5 nitro 4 pyrimidinol. TABLE 1EMI36.1 EMI36.2 tb Ar SEP or SEP Ar tb 2 Thienyl tb SEP S tb 3 Thienyl tb SEP S tb 3 Furanyl tb SEP o tb 2 thienyl SEP methyl tb SEP , tb SEP E2C tb 3 He 2 nh enyl SEP 3C tb SEP 3 tb 2 Me 3 thienyl tb TABLE 1 CONT D EMI37.1 tb Ar SEP or SEP Ar tb 5He 2 thienyl tb SEP , tb SEP S SEP SEP CH3 tb Pyridinyl SEP Q tb SEP 101 tb BellzoLb thien 2 yl tb SEP MY tb 2 tniazolyl tb SEP tSX tb 4 thiazolyl tb SEP 1 SEP tb SEP S tb tnienyl methyl tb SEP H2C tb c SEP tb 5 Me 3 thienyl SEP 9 tb SEP S SEP C Ir tb TABLE 1 CONT D EMI38.1 tb Ar SEP or SEP Ar tb 5 Ke 2 furanyl tb SEP CB3 tb 4 de 3 thienyl SEP CH3 tb SEP s9 tb 4 5e 2 thienyl SEP 17 CH3 tb SEP 9Sss tb RTI ID 38.1 EXAMPLE 12 2,5 Diamino 4 2 thienylmethyl amino pyrimidin 6 ol, dihydrochloride a compound of Scheme 2, Formula IVa, wherein n is one, m is zero, 4 and R5 are eacri hydrogen, and Ar is 2 thienyl She crude N formyl derivative as prepared in Example lu above 4 g, 0.1508 mole was suspended in anhydrous methanol 5u ml and a stream o dryHCl g was passed through the solution while heating the mixture at reflux.The reaction was continued for 2.5 hour when a clear solution was formed followed by a crystalline precipitate. The mixture was cooled in an ice bath and then filtered to give the salt, 2,5 diamino 4 2 thienylmethyl amino pyrimidin 6 ol, dihydrochloride, 28.6 g . Concentration of the mother liquor gave an additional amount of tne salt 8.65 g . Total yield, 37.25 g 79 . The material was carried on without further purification. Alternatively, the N formyl derivative was refluxed with 5 methanolic SC1 g to give the desired diamine 2 HCl salt. EXAMPLE 12A The procedure described in example 12 was repeated to prepare the following 2,5 diamino 4 t heteroaryl or substituted heteroaryl methyl amino pyrimidin 6ol, as dihydrochloride salt Table 2 , starting from appropriate 2 amino 4 heteroaryl or substituted heteroaryl methyl amino 5 formamido 6 pyrimidinol Table 1 . TABLE 2EMI39.1 EMI39.2 tb Ar SEP or tb 3 Thienyl tb SEP tb SEP S tb 2 Furanyl tb SEP Jjn, tb SEP A02 tb 3 Furanyl tb TABLE 2 CONT D EMI40.1 tb Ar SEP or SEP Ar tb 2 thienyl methyl SEP e tb SEP S tb 3 Me 2 th SEP ienyl SEP E3C tb SEP 5 tb 2He 3 thlerLyl tb SEP H SEP C tb 5 3e 2 tienyl tb 2 Pyridinyl SEP tb Benzoft nien 2 yl SEP tb 2 tiazoll SEP ,, tb TABLE 2 CONT D EMI41.1 tb SEP Ar tb Ar SEP or SEP Ar tb 4 tniazolyl tb SEP 3 tnienylEmethyl SEP 2 SEP X tb 5 Me 3 thienyl SEP Am tb SEP 2 tb 5 fe 2 furanyl SEP AnX tb SEP 4 He 3 tAienyl SEP E3 tb SEP E3 tb SEP 4 ie 2 thienyl tb SEP D7W SEP CE3 tb EXAMPLE 13Methyl 2 Amino 1,6 dihydro 6 oxo 4 2 thienylmethyl amino 5 pyrimidinyl amino thioxomethyl carbamate A compound of Scheme 2, Formula II wherein R6 is methyl, n is one, m is zero, R4 andR5 are each hydrogen and Ar is 2 thienyl The crude dihydrochloride salt as prepared in Example 12 above 37.2 g, 0.12 mole was suspended in water 300 ml and then basified witn a mixture of concentrated NH4OH and 97 hydrazine 3 1 40 ml to give the free base which was dried over vacuum over P205 for 20 hours. Yield 26.1 g 978 of the base shown as compound of scheme II,Formula IVS wherein n, m, R4, R5, and Ar are as defined above. This free base was unstaole. A suspension of potassium thiocyanate ld.i g 0.186 mole in acetonitrile 250 ml was treated with methyl chloroformate 99 13.8 ml, 0.177 mole and the mixture was heated at reflux for one hour, cooled, and tnen filtered to remove inorganic salts.The bright yellow colored filtrate is stirred overnight at room temperature under nitrogen. Care should be tasen so that all of the methylchloroformate has reacted before proceeding. The dry base 26.1 g was added to the solution of methoxycarbonyl isothiocyanate and the stirring continued for 36 flours at room temperature under nitrogen. The reaction was monitored to completion by TLC SiO2 20 CH3OH inCHCl3 . The product was filtered o and wasned with methanol to give the tniourea derivative, methyl 2 amino 1,6 dihydro 6 oxo 4 2 thienylmethyl amino 5 pyrimidinyl amino thioxomethyl carbamate.Yield 37.4 g 96 , mp 225 226 C 96.6 pure byHPLC . Alternatively, the nitro or nitrosopyrilnidines were catalytically reduced and reacted immediately with ethoxycarbonyl isothiocyanate to give the thiourea derivative. This material was carried on to the next step without further purification. EXAMPLE 13A The procedure described in Example 13 was repeated to prepare the following methyl or ethyl 2 amino 1,6 dihydro 6 oxo 4 heteroaryl or substituted heteroaryl methyl amino 5 pyrimidinyl amino thioxomethyl carbamate Table 3 starting fro appropriate 2,5 diamino 4 heteroaryl or substituted heteroaryl methyl amino pyrimidin 6 ol dinydrochloride salt Table 2 . TABLE 3EMI44.1 EMI44.2 tb Ar SEP or SEP Ar tb 2 hAienyl SEP 5Th SEP Et tb 3 Thienyl SEP 7w. SEP CH3 tb 2 Furanyi SEP 4 SEP CH3 tb 3 SEP Furanyl SEP CH3 tb SEP mp SEP mp SEP 246 249 SEP C tb SEP dec tb SEP 2 SEP thienyl SEP methyl SEP H2CC SEP CEJ tb SEP 234 239 C tb SEP SEP EzC SEP S SEP dec tb 2 Me 3 thleny, SEP I SEP CH3 tb SEP H3C SEP 2 SEP mp SEP 235 23z C tb SEP g3C SEP 5 SEP dec tb TABLE 3 CONT D EMI45.1 tb Ar SEP or SEP Ar tb 5 Me 2 SEP thienyl SEP CH31 tb SEP S SEP mp SEP 227 230 SEP C tb SEP 013 SEP dec tb 2 Me 2 thienyl SEP SEP Et SEP Et tb 2 Pyridinyl SEP t SEP CH3 tb BenzotbJthien 2 yl SEP SEP CH3 tb SEP N tb 2 thiazolyl SEP 1N tb SEP S SEP mp SEP 214 215 tb 4 thiazolyl SEP SEP cm3 tb SEP mp SEP 217 218 2 tb SEP E SEP C SEP tb SEP 3 SEP thienyl SEP SEP methyl SEP t SEP y SEP CH3 tb SEP S tb 5 Me 3 SEP thienyl SEP fACH SEP CH3 tb SEP 3 tb TABLE 3 CONT D EMI46.1 tb Ar SEP or SEP Ar tb 5 Me 2 furanyl SEP CH3 tb SEP mp SEP mp SEP 228 229 C tb SEP O SEP CE3 tb SEP 3 tb 4 He 3 thienyl SEP CBJ SEP CH3, SEP Et tb SEP s tb 4 Me 2 edienyl SEP CEf3 SEP CH3, SEP Et tb SEP A5 tb EXAMPLE 14Methyl 5 amino 7 2 thienylmethyl amino oxazolo 5,4 d pyrimidin 2 yl carbamate SeeScheme 2, Formula III wnerein R6 is methyl, n is one, m is zero, R4 and R5 are each hydrogen and Ar is 2 thienyl A mixture of the thiourea derivative as prepared in Example 13 35 g 0.096 mole and N,N dicyclohexylcarbodiimide DCC 59.4 g, 0.286 mole was suspended in dry DMF 1800 ml and stirred at room temperature for 24 hours. The course of the reaction was followed by TLC SiO2 20 , CH3OH in CHCl3 .The DMF was completely stripped off under vacuum and the residue triturated twice witn CH2C12 to give the desired carbamate, methyl E5 amino 7 2 thienylmethyl amino oxazolo 5,4 d pyrimidin 2 yljcarbamate. Yield 27.8 g 90i , mp 300 C. Purity 97.6 HPLC . This material was carried on to the next step without further purification. EXAMPLE 14A The procedure described in Example 14 was repeated to prepare the following methyl or ethyl 5 amino 7 LC heteroaryl or substituted heteroaryl methyl amino oxazolo 5,4 d pyrimidin 2 yl carbamate Table 4 starting from appropriate methyl or ethyl 2 amino 1,6 dihydro 6 oxo 4 heteroaryl or substituted heteroaryl methyl amino 5 pyrimidinyl amino thioxomethyl carbamate Table 3 . TABLE 4EMI48.1 EMI48.2 tb Ar SEP or SEP Ar SEP Rg tb 2 Thienyl SEP X SEP Et tb SEP I tb 3 hienyl SEP C SEP WH3 SEP CH3 tb SEP C tb 2 SEP Furanyl SEP a SEP C3 tb SEP 80i tb 3 Furanyl SEP n SEP CH3 tb SEP I SEP mp SEP 283 291 tb SEP XOZ SEP dec tb 2 thienyl m thyl SEP methyl tb SEP g SEP mp SEP 270 tb SEP H2CS SEP dec tb 2 Me 3 SEP thienyl SEP Ct 3 tb SEP .1 SEP ss SEP mp SEP 270 c tb SEP H3C SEP dec tb TABLE 4 CONT D EMI49.1 tb Ar SEP or SEP Ar SEP R tb S SEP Me 2 thienyl SEP CH3, SEP CH3, SEP Et tb SEP 2 SEP p SEP ,250C tb SEP CH SEP dec SEP dec tb SEP 3 SEP dec tb 2 Pyridinyl SEP X SEP CH3 tb BenzoLbjthien 2 yl SEP Cfi3 tb 2 thiazolyl SEP CB3 tb 4 t.niazslyl SEP N SEP SEP CH3 tb SEP 3 thienyl methyl SEP CH.3 tb SEP E SEP C tb SEP l SEP f tb 5 Ke 3 hienyi SEP rnJ tb SEP 3 tb TABLE 4 CONT D EMI50.1 tb Ar SEP or SEP Ar SEP R6 tb 5rMe 2 furanyl SEP CH3 tb SEP I tb 5 Me SEP 2 thienyl SEP CH31 SEP Et tb SEP S SEP CR3 tb 5rde 3 thienyl SEP yCR3 SEP CH3 tb SEP M SEP 3 tb 4 Me 2 thienyl SEP CR3 SEP 3 SEP Et tb SEP g SEP p 200iC tb SEP S SEP dec tb EXAMPLE 15Methyl 2 amino 6,9 dihydro 6 oxo 9 2 thienylmethyl1H purin 8 yl carbamate See Scheme 2, Formula I wherein R3 is NHCOOR6 Wherein R6 is methyl, n is one, m is zero, R4 and R5 are each hydrogen andAr is 2 thienyl A mixture of the oxazolocarbamate as prepared in Example 14 25 g 0.078 mole and anhydrous K2CO3 was suspended in anhydrous methanol and heated to reflux for eignt hours. The course of the reaction is being followed by the TLC system mentioned above.The reaction mixture was then evaporated to dryness under reduced pressure and the residue dissolved in ammonium chloride solution 16.8 g 0.312 mole in 200 ml of water . The resulting precipitate was collected and dried giving 24.39 g of the methylE2 amino 6,9 dihydro 6 oxo 9 2 thienylmethyl lH pyrin 8 yl carbamate, sometimes contaminated with the 8 amino compound, i.e., in this example, 89.58 carbamate and 9.54 8 amino compound, 8 amino 9E 2 thienyl methyl guanine of Formula I wherein R3 is NH2. This material was carried on to the next step without further purification. EXAMPLE 15A The procedure described in Example 15 was repeated to prepare the following methyl or ethyl 2 amino 6,9 dihydro 6 oxo 9 heteroaryl or subtituted heteroaryl methyl 1H purin 8 yl carbamate Table 5 starting from appropriate methyl or ethyl L5 amino 7 heteroaryl or substituted heteroaryl methyl amino oxazolo 5,4 d pyrimidin 2 yl carbamate Table 4 . TABLE 5EMI52.1 EMI52.2 tb Ar SEP or SEP Ar SEP R6 tb 2 Thienyl SEP Et, SEP j p tb SEP 7 SEP 250 C SEP dec tb SEP S tb 3 Tnienyl SEP SEP CH3 tb SEP tS tb 2 Furanyl SEP Ch3 tb SEP I SEP sp SEP ,300 C tb SEP SEP dec tb 3 SEP Furanyl SEP CY3 tb SEP mp SEP P SEP 270 SEP C tb SEP dec tb 2 thienyl SEP methyl SEP c 3 tb SEP H2C tb 2 M 3 thienyl tb SEP I. SEP tb SEP I, SEP tb SEP E SEP cs SEP XS tb TABLE 4 CONT D EMI53.1 tb Ar SEP or SEP Ar SEP a6 tb 5 SEP Me 2 SEP thienyl SEP CH3, SEP Et tb SEP CEI3 SEP ap SEP ,ZSO C tb SEP mp SEP S SEP 250 C tb SEP 013 SEP dcc tb 2 SEP Pyridinyl SEP SEP CH3 tb BezoCblthien 2 yl SEP Cii3 tb SEP 19 SEP t tb 2 iazolyl SEP N SEP CH3 tb SEP 3 tb 4 thiazolyl SEP N SEP SEP C3 tb SEP ,. SEP tb 3 thinyl methyl SEP EC SEP CH tb SEP C tb SEP Ci tb de i .ieny SEP 3 tb SEP SEP tb SEP sl SEP cs tb TABLE 4 CONT D EMI54.1 tb Ar SEP or SEP Ar SEP R6 tb S SEP Me 2 SEP furanyl SEP CH3 tb SEP mp SEP mp SEP 250 C tb SEP OCH3 SEP tss SEP CE3 SEP dec tb 4 Me 3 edienyl SEP enyl SEP CH SEP CH3, SEP Et tb 4 Me 2 thienyl SEP SEP CH3 SEP CA SEP 3, SEP Et tb EXAMPLE 16 8 Amino 9 2 thienyl methyl guanine See Scheme 2Formula I herein R3 is NH2, n is one, 3 is zero,R4 and R5 are each hydrogen and Ar is 2 thienyl The crude carbamate as prepared in Example 15 89.5 the carbamate plus 9.5 the 8 amino compound 20.39 g 0.064 mole from the previous reaction is suspended in isopropanol 125 ml and 1 N HCl 125 ml 0.125 mol and the mixture heated at reflux for 2 hours the reaction is monitored by TLC SiO2 20 MOH in CHCl3 CH3CN HOAc H2O 8 1 1 , when a clear solution is formed. On cooling the product crystallizes out from the solution as the hydrochloride salt of 8 amino 9 2 thienyl methyl guanine. Yield 15.1 g 764 . Purity 98 byHPLC, mp 219 222 C dec . The hydrolysis was also carried out in 10 methanolic sodium hydroxide solution under refiux temperature, followed by neutralization and recrystallization from appropriate solvent. EXAMPLE 16A The procedure described in Example 16 was repeated to prepare the following 8 amino 9 hetero aryl or substituted heteroaryl methyl guanines Table 6 starting from appropriate metnyl or ethyl 2 amino 6,9 dihydro 6 oxo 9 heteroaryl or substituted heteroaryl methyl 1H purin 8 yl carbamate Table 5 . TABLE 6EMI55.1 EMI55.2 tb Ar SEP or SEP X SEP mp SEP C tb 2 Furanyl SEP t SEP iCl SEP 25a 7 tb a. SEP 3 Thienyl SEP 1 FiZO SEP 275 d tb SEP d tb TABLE 6 CONT D EMI56.1 tb Ar SEP or SEP Ar SEP X tb b. SEP 3 Furanyl SEP 9 SEP HCl SEP 293 4 tb SEP d tb c. SEP t2 tnieslylXmethyl SEP HC1 SEP H2O SEP 153 5 tb SEP 3 SEP te tb SEP H2C SEP S tb SEP H2C tb d. SEP 2 Me 3 thienyl SEP C1 SEP il tb SEP 7 SEP d tb SEP H3C SEP S tb e. SEP 5 Me 2 t,hienylw SEP 1 SEP O. SEP 25 SEP 22 tb SEP 7 CH3 SEP 20 tb f. SEP 2 Pyridinyl SEP e SEP 1.5 SEP HCl SEP 270 2 tb SEP off SEP 2 SEP SEP ii tb X. SEP 3enzotbjthin 2 yI SEP iw. SEP 25 SEP n20 SEP 300 tb SEP a tb TABLE 6 CONT D EMI57.1 tb Ar SEP or SEP Ar SEP x SEP mp C tb h. SEP 2 thiazolyl SEP N SEP 1.2 SEP HC1 SEP 250 tb SEP 1.2 SEP H20 tb SEP S tb i. SEP 4 thiazolyl SEP N SEP 1.1 SEP dC1 SEP 250 tb SEP i SEP 0.3 SEP B20 tb SEP S tb j. SEP v3 hie. yl ,methyl SEP 0.9 SEP 9. SEP Cl SEP 177 63 tb SEP H20 SEP a tb SEP SEP H2C tb k. SEP 5 Me 3 thienyl SEP HS O.5 SEP 5 SEP 212 5 tb SEP d tb SEP l5 tb SEP SEP SCH SEP 3 tb 1. SEP i Me 2 f uranyl SEP C I. 5 SEP 212 4 tb SEP n SEP ai SEP 2W tb SEP 3 tb TABLE 6 CONT D EMI58.1 tb Ar SEP or SEP Ar SEP X SEP mp C tb SEP 240 tb m. SEP 4 Me 3 thienyl SEP 0.9 SEP HC1 SEP 240 tb SEP SEP CH3 SEP 1.25 SEP H20 SEP d tb n. SEP 4 Me 2 thienyl SEP yCH3 tb EXAMPLE 17 2,8 Diamino 1,9 dihydro 9 2 thienylmethyl 6H purine6 thione A mixture of P2S5 2.4 g 10.95 mmol , pyridine 30 ml and 8 amino 9 2 thienyl methyl guanine 1.5 g 4.87 mmol was heated under reflux for 4.5 ours an then poured into 200 ml of boiling water and boiled for one hour. The mixture was allowed to stand at room temperature overnight.The precipitated solid was collected, dissolved in 1 NNaOH, treated with activated charcoal, filtered, and then acidified with glacial acetic acid to pH 5.4. Tne precipitated solid was collected, dissolved inL 2i HCl, treated with activated charcoal, filtered, and neutralized with NH4OH to pH 7.07 to give 542 mg of th desired product, mp 300 C. EXAMPLE 17A The procedure described in Example 17 was repeated to prepare the following 2,8 diamino 1,9 dihydro 9 heteroaryl or substituted heteroaryl methyl 6H purin 6 thione, starting from appropriate 8 amino 9 heteroaryl or substituted heteroaryl alkyl guanine. 2,8 Diamino 1,9 dihydro 9 3 thienylmethyl 6Hpurine 6 thione, 0.5 H20, mp 2750C dec . 2,8 Diamino 1,9 dihydro 9 2 2 thienyl ethyl 6H purine 6 thione, 0.25 H20, mp 260iC dec . EXAMPLE la 2 Amino 7,9 dihydro 9 2 thienylmethyl 1H purine6,8 dione A mixture of 8 bromo 9 2 thienyl methyl guanine see Example 5 3.12 g 9.56 mmol , acetic anhydride 75 ml , glacial acetic aci 75 ml ann anhydrous sodium acetate 14.9 g 0.1816 mol was heated to reflux for 20 hours. The dark solution which formed was then evaporated to dryness under reduced pressure. The residue was dissolved in aqueous methylamine 150 ml , stirred at room temperature for 48 hours and then heated to reflux for 2.5 hours. The methylamine was distilled off under reduced pressure and the residue was recrystallized from boiling methanol water mixture to give 1.23 g of the analytical product, mp 300 C. EXAMPLE 19 2 Amino 1,7,8,9 tetrahydro 9 2 thienylmethyl 8thioxo 6H purin 6 one A mixture of 8 bromo 9 2 thienyl methyl guanine see Example 5 2.0 g 6.13 mmol , DMF 250 ml , and thiourea 0.93 g 12.26 mmol was heated under reflux for 20 hours and thin the solvent was evaporated to dryness under reduced pressure. The residue was dissolved in 1N NaOH, treated with charcoal, filtered, and acidified with glacial AcOH to give a pale yellow solid. Analytical sample was prepared by repeating the purification process, yield 709 mg mp 280 C. EXAMPLE 20N,N 6,9 dihydro 6 oxo 9 2 thienylmethyl 1H purin2,8 di yl bis acetamide A mixture of 8 amino 9 2 thienyl methyl guanine 0.5 g 1.88 mmol , DMF 10 ml , pyridine 5 ml , and acetic anhydride 5 ml was stirred at room temperature for 36 hours. The mixture was diluted with ether 50 i and filtered to give analytically pure product, mp 243 4 C. STARTING MATERIALS Starting materials are prepared as follows using a known procedure or following a procedure analogous to that known in the art. 5 Methyl 2 thienylmethylamine, H. Hartough, et alJ. Am. Chem. Soc., 1948, 70 4018. Benzo b thiophen 2 yl methylamine, D. Shirley, et al, J. Atn. Chem. Soc., 1952, 74 664. 3 Methyl 2 thienylmethylamine, H. Hartough, et al,J. Am. Chem. Soc., 1948, 70 4018. Benzo b thiophen 3 yl methylamine was prepared by Gabriel Synthesis from the corresponding chloro compound W. King, et al, J. Org. Chem., 1948, 13 635 . 2 Methyl 3 thienylmethylamine was prepared by lithium aluminium hydride LAH reduction of the corresponding nitrile M. Janda, et al, Coll. Czech. Comm., 1974, 39 959 . 2 2 thienyl ethylamine and 2 3 thienyl ethylamine were prepared by the lit. method of W. Hertz, et al, in J. Am. Chem. Soc., 1951, 73 351. 2 Methyl 4 thienyl methylamine was prepared byLAH reduction of 2 methyl 4 cyano thiophene which was prepared from the corresponding 4 bromo compound Y. Goldfarb, et al, Zh. Obs. Khim. 1964, 34 969 and CuCN. 3 Methyl 4 thienylmethylamine was similarly prepared as follows EMI61.1 4 Methyl 2 thienylmethylamine was prepared byLAH reduction of the corresponding aldoxime. 2 and 4 Thiazolylmethyl amines were prepared according to the literature procedures R. G. Jones, et al, J. Am. Chem. Soc., 1950,72 4526 . FORMULAEMI62.1